secwatch.observer — SEC 8-K summary ====================================== Issuer: Zymeworks Inc. (ZYME) CIK: 0001937653 Form: 8-K Filed at: 2026-10-23T10:07:04+00:00 Accession: 0001937653-26-000055 Event type: m_and_a Sentiment: positive Materiality: 0.85 Item codes: 1.01, 7.01, 9.01 LLM model: deepseek-v4.1-flash:cloud@v2 Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones -------------------------------------------------------------------------------- - Roche pays $55M upfront after HSR clearance, plus a $40M milestone on the first ZW209 Phase 1b trial; up to $718M in development, commercial and sales milestones. - Zymeworks also gets tiered high-single-digit to mid-teen royalties on global net sales, payable until the later of 10 years post-launch or patent expiry (patents into the 2040s). - Zymeworks runs the Phase 1a monotherapy trial at Roche's expense; Roche funds it and takes over all later global development, manufacturing and commercialization. - Exclusive worldwide license covers ZW209 and other DLL3 trispecific T-cell engagers; Zymeworks is barred from DLL3 T-cell engager work for up to 5 years or first Phase 3 start. - FDA IND clearance for ZW209 received; deal still subject to HSR waiting period; investor call October 27 at 8:30 am ET. Source: EDGAR index: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/0001937653-26-000055-index.htm Primary doc: https://www.sec.gov/Archives/edgar/data/1937653/000193765326000055/zyme-20261022.htm HTML page: https://secwatch.observer/filing/0001937653-26-000055 License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer